Compare Novartis with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GLENMARK PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GLENMARK PHARMA NOVARTIS/
GLENMARK PHARMA
 
P/E (TTM) x 493.6 12.5 3,937.3% View Chart
P/BV x 28.6 1.8 1,597.8% View Chart
Dividend Yield % 1.6 0.5 295.6%  

Financials

 NOVARTIS   GLENMARK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
GLENMARK PHARMA
Mar-19
NOVARTIS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs758712 106.5%   
Low Rs579484 119.7%   
Sales per share (Unadj.) Rs228.4349.6 65.3%  
Earnings per share (Unadj.) Rs31.732.8 96.8%  
Cash flow per share (Unadj.) Rs32.844.3 73.9%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.50.3 447.0%  
Book value per share (Unadj.) Rs297.1198.6 149.6%  
Shares outstanding (eoy) m24.69282.17 8.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.91.7 171.3%   
Avg P/E ratio x21.118.2 115.5%  
P/CF ratio (eoy) x20.413.5 151.4%  
Price / Book Value ratio x2.23.0 74.8%  
Dividend payout %31.56.1 516.4%   
Avg Mkt Cap Rs m16,505168,625 9.8%   
No. of employees `0000.712.0 5.5%   
Total wages/salary Rs m1,44520,561 7.0%   
Avg. sales/employee Rs Th8,441.38,196.0 103.0%   
Avg. wages/employee Rs Th2,163.61,708.1 126.7%   
Avg. net profit/employee Rs Th1,173.1768.5 152.7%   
INCOME DATA
Net Sales Rs m5,63998,655 5.7%  
Other income Rs m1,7182,081 82.6%   
Total revenues Rs m7,357100,736 7.3%   
Gross profit Rs m-6315,858 -0.4%  
Depreciation Rs m253,259 0.8%   
Interest Rs m553,346 1.7%   
Profit before tax Rs m1,57511,335 13.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m7923,756 21.1%   
Profit after tax Rs m7849,250 8.5%  
Gross profit margin %-1.116.1 -6.9%  
Effective tax rate %50.333.1 151.6%   
Net profit margin %13.99.4 148.2%  
BALANCE SHEET DATA
Current assets Rs m9,52266,968 14.2%   
Current liabilities Rs m3,29640,211 8.2%   
Net working cap to sales %110.427.1 407.1%  
Current ratio x2.91.7 173.5%  
Inventory Days Days3783 43.9%  
Debtors Days Days2881 35.0%  
Net fixed assets Rs m4633,322 0.1%   
Share capital Rs m123282 43.7%   
"Free" reserves Rs m7,21355,770 12.9%   
Net worth Rs m7,33656,052 13.1%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m11,105132,888 8.4%  
Interest coverage x29.54.4 672.0%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.7 68.4%   
Return on assets %7.69.5 79.7%  
Return on equity %10.716.5 64.7%  
Return on capital %22.217.8 124.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6162,998 0.1%   
Fx outflow Rs m3,63022,859 15.9%   
Net fx Rs m-3,57040,140 -8.9%   
CASH FLOW
From Operations Rs m1,61013,242 12.2%  
From Investments Rs m687-6,990 -9.8%  
From Financial Activity Rs m-2,677-7,387 36.2%  
Net Cashflow Rs m-380-2,971 12.8%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 6.9 29.0%  
FIIs % 1.6 34.4 4.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.5 204.8%  
Shareholders   41,647 56,727 73.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  ALEMBIC LTD  ALEMBIC PHARMA  ELDER PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 17, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS